Ron (Yuren) Wang, Ph.D., is the Head of Portfolio Management for Adagene. Dr. Wang has over 20 years of drug discovery and development experience in large pharmaceutical and biotech companies, making significant contributions to the scientific development of various drugs. During his career, he has led or integrally participated in over 20 projects from novel target validation, drug discovery, and biomarker strategy to preclinical candidates.
Prior to joining Adagene, Dr. Wang served as Vice President of R&D research for Jemincare Therapeutics (USA), responsible for the scientific evaluation of projects, in-licensing and portfolio management. Before that, he was the Senior Director of Business Development in Reaction Biology Corporation (RBC), where he led custom service in drug discovery of protein kinases and cancer epigenetic areas. Dr. Wang was also a project leader in metabolic disease of Bristol Myers Squibb and Wyeth Neuroscience Research (now owned by Pfizer).
Dr. Wang received his Ph.D. in molecular and cellular biology from the University of Pennsylvania and completed his postdoctoral training in molecular pharmacology at Dr. David Manning’s laboratory at the University of Pennsylvania. He has published more than 30 research papers in peer-reviewed journals and is the inventor of multiple patents.